Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin specific peptidase 10 (USP10) is a member of the ubiquitin-specific protease (USP) family of deubiquitinating enzymes. It specifically cleaves ubiquitin from conjugated protein substrates and is involved in diverse cellular processes including protein degradation, DNA damage response, autophagy, cell signaling, and immune regulation. USP10 acts through its cysteine protease activity and regulates several clinically significant targets such as p53, Beclin1, CFTR, and PTEN. It localizes in both the nucleus and cytoplasm and modulates cell fate in a context-dependent manner, functioning as either a tumor suppressor or oncogene depending on cellular background and pathological state. USP10 is being investigated as a therapeutic target for cancer, neurodegenerative diseases, and conditions involving disrupted ubiquitin signaling[1][3][4][5][9][11].
USP10 inhibitors block deubiquitinating activity leading to increased ubiquitination and degradation of USP10 substrates (such as p53, Beclin1, CFTR), impacting cell cycle, apoptosis, autophagy, or stress responses[1][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin specific peptidase 10 (USP10).